MedTrace Logo

Adherence to PTH(1-84) Treatment (FP-002-IM)

NCT00478569 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1179

Last updated 2014-05-28

Study results available
· View outcomes & findings →

Summary

The primary objective is:

1\) to describe adherence (and the main factors influencing adherence) to PTH(1-84) treatment when prescribed in a normal clinical setting.

The secondary objectives are:

1. to describe the demographics and clinical characteristics of the patients that in a normal clinical setting are started on a treatment regimen with PTH(1-84)
2. to describe (using available data) the long term treatment effectiveness during the 24 months following initiation of PTH(1-84) treatment in a normal clinical setting
3. to monitor safety for 24 months following initiation of PTH(1-84) treatment in a patient in a normal clinical setting.

Conditions

  • Clinical Use of PTH(1-84)

Interventions

DRUG

Parathyroid Hormone (PTH) (1-84)

Adherence to PTH(1-84) treatment in Usual Clinical Settings

Sponsors & Collaborators

Principal Investigators

  • Medical Director, Clinical Science · Takeda

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00478569 on ClinicalTrials.gov